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Tritium-labeled (+)-pentazocine (PHI-lb) of specific activity 26.6 Ci/mmol was synthesized in 3 steps starting with 
(+)-normetazocine (2) of defined optical purity. PHI-lb has been characterimd as a highly selective ligand for labeling 
of c receptors. Competition data revealed that PHI-lb could be displaced from guinea pig brain membrane preparations 
with a number of commonly used IJ receptor ligands. PHI-lb exhibited saturable, enantioselective binding with a & of 
5.13 f 0.97 nM and a ZI,, of 1146 f 122 fmol/mg protein. Phencyclidine (PCP) displaced PHI-lb with low affinity while 
MK-801 was inactive, thus indicating insignificant activity at the PCP-binding site; apomorphine failed to displace PHI-lb 
indicating lack of dopamine receptor cross-reactivity. Since the atlinity of PHI-lb is about 6 times that of the two com- 
monly employed 0 ligands (( +)-3-PH]PPP and PH]DTG) and since it is mom selective for u receptors than the benzo- 
morphan PH]SKF-10,047, it represents the first example of a highly selective benzomorphan based o receptor ligand. 
PHI-lb should prove useful for further study of the structure and function of o receptors. 
Pentazocine, (+)-PHI-; Receptor, o; Scatchard analysis; Radiolabeling 
1. INTRODUCTION 
Numerous attempts have been made to identify 
a potent analgesic without the addiction liability 
and side effects associated with the use of mor- 
phine and other classical narcotics. Highly signifi- 
cant advances have been made in this area with the 
introduction of the agonist-antagonist drugs 
buprenorphine (Buprenex), nalbuphine (Nubaine) 
and butorphanol (Stadol). Early work in this area 
following the introduction of the 6,7-benzomor- 
phans as analgesics by May and his associates [l] 
resulted in evaluation of a series of racemic N-alkyl 
substituted 2-hydroxy-$Pdimethyl-6,7-benzomor- 
phans of which the 3,3-dimethylallyl derivative 
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[( *)-pentazocine, Talwin] [2] emerged as the first 
clinically useful narcotic agonist-antagonist. Initial 
studies showed the analgesic activity to reside pre- 
dominantly in the (- )-enantiomer, la (fig. 1) 131, 
as the (+)-isomer, lb, was found to be l/20 as 
potent as la [3]. 
Later investigations revealed that ( + )- 
pentazocine (lb) is a highly potent and selective 
ligand for g receptors [4,5]. 0 receptors bind cer- 
tain antipsychotic drugs, psychotomimetic ( + )- 
opiates, and phencyclidine (PCP) [6]. However, g 
sites are pharmacologically distinct from either 
dopamine, opiate, or PCP receptors. Studies both 
in vivo and in vitro have demonstrated that c sites 
are functional. They have been implicated in con- 
trol of motor behavior [7], regulation of smooth 
muscle contraction [8,9], regulation of neurotrans- 
mitter release [9], and modulation of the phospho- 
inositide second messenger system [lo]. (T sites have 
also been implicated in the motor disorder, dysto- 
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nia [7,11]. It is also possible that these sites 
mediate at least some of the psychotomimetic ac- 
tions of benzomorphans such as ( +)-N- 
allylnormetazocine, and PCP related compounds, 
as well as the antipsychotic effects of drugs such as 
haloperidol. 
In order to study the binding characteristics of c 
sites in vivo and in vitro, it is necessary to have 
radiolabeled probes with high affinity and selec- 
tivity for the receptor. At present, there are only 
four available radiolabeled probes for 0 receptors. 
These are [3H]haloperidol [12], ( +)-3-[3H]-(3-hy- 
droxyphenyl)-N-( I-propyl)piperidine (( + )-3-[3H]- 
PPP) [12], 1,3-[3H]di-(o-tolyl)guanidine ([3H]- 
DTG) [ 131, and ( + )-iV-[3H]allylnormetazocine 
(( +)-[3H]SKF-10,047 [4]). Two of these, 
[3H]haloperidol and ( +)-[3H]SKF-10,047, are 
limited by their substantial cross-reactivity with 
other receptors. We thus wished to synthesize op- 
tically pure (+ )-[3H]pentazocine ([3H]-1b) (fig. 1) 
for evaluation as a g ligand and now report this 
compound is a highly potent and selective drug 
which promises to be an extremely valuable 0 
receptor probe. The requirement of optically pure 
ligands for most meaningful drug receptor studies 
has been discussed earlier and is well known [14]. 
2. MATERIALS AND METHODS 
2.1. Chemical synthesis 
Spectra from nuclear magnetic resonance (Varian XL300 
spectrometer), infrared (Beckman 3001 instrument), and 
chemical ionization (CI) mass spectra (Finnegan Mat-3 11 spec- 
trometer) were in accord with the assigned structures. Gas 
chromatographic analysis (CC) was performed on a Hewlett- 
Packard 5880A instrument with a carbowax capillary column 
and a flame ionization detector. Melting points were obtained 
using a Thomas-Hoover Unimelt apparatus, and are uncor- 
rected. Specific rotation values were recorded at the sodium-D 
line using a Perkin-Elmer 241 MC polarimeter. Thin layer 
chromatographic analysis (TLC) was performed on Analtech 
silica gel (GHF) plates. Solvent system A refers to concentrated 
aqueous NHs-MeOH-CHCl3 (1: 9: 90); solvent system B refers 
to concentrated aqueous NHs-MeOH-CHCl3 (2 : 18 : 80). All 
new compounds gave combustion analyses for carbon, 
hydrogen and nitrogen within + 0.4% of the calculated value 
and were performed at Atlanta Microlabs, Atlanta, GA, USA. 
All tritium-labeled compounds co-migrated with their unlabeled 
counterparts on TLC as above; their radiochemical purity was 
assessed using a Berthold model LB2760 TLC scanner. Specific 
activity measurements for radiolabeled compounds were deter- 
mined by ultraviolet (UV) analysis with a Hewlett-Packard HP 
8450A UV/VIS spectrophotometer. 
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2.2. Optically pure (+)-cis-2 ‘-hydroxy-5,9-dimethyl-6,7- 
benzomorphan [(+)-21, I(+)-normetazocine)] 
In a modification of the procedure of Tullar et al. [3], 
racemic 2 [l] (20.0 g, 0.092 mol) was dissolved in 240 ml of 
distilled water containing 6.92 g (0.046 mol) of (-)-tartaric 
acid. After 1 h, a white precipitate had formed which was 
filtered and washed with a small amount of cold water. The 
material was recrystallized twice from water and dried in vacua 
at 60°C overnight to give 11.42 g of (+)-2.(-)-tartrate, m.p. 
306-307°C. Reported [3] m.p. 305-308°C. 
The base was regenerated and the optical purity determined 
as follows: a small portion of the salt (1.0 g) was placed in a 
50 ml flask with CHCl3 (15 ml), 3 ml water and 3 ml cont. 
NHdOH solution and stirred for 20 min. The CHCl3 layer was 
filtered through NazS.04 and concentrated to provide (+ )-2 free 
base, m.p. 260-262”C, [cu12’D = +70.0” (c = 0.5, methanol). 
Reported [3] m.p. 260-262°C [cu]“D = +70.1” (c = 1, 
ethanol). The (+)-2 (50 mg) was dissolved in 2 ml of dry DMF 
and optically pure (s)-( -)-cu-methylbenzylisocyanate (27 mg, 
0.8 equiv.) 114) was added in one portion via syringe and the 
resulting solution was stirred overnight. The solution was then 
partitioned between 5 ml water and 5 ml diethyl ether. The 
aqueous layer was removed, and the ethereal ayer was ex- 
tracted with 5 ml of 1 N HCl solution. The ethereal layer was 
then dried (NazSOd). A small amount of impurity [N,N ‘-bis-(cu- 
methylbenzyl)urea] which could be detected by GC was re- 
moved by filtration through a short pad of silica gel. The 
filtrate was concentrated to give urea 5. Similarly, the previous- 
ly described procedure was carried out using a sample of (+)-2 
to provide a mixture of diastereomeric ureas. The 300 MHz ‘H- 
NMR spectra of the urea prepared from the (+)-base showed 
methyl doublets at 6 1.51 and 1.46 ppm for the diastereomeric 
u-methyl groups. No doublet at 6 1.46 was detectable in the 
spectrum of the urea prepared from the (+ )-base indicating 
99+ % optical purity [15]. 
benzomorphan (3) 
2.3. (+)-cis-2 ‘-Hydroxy-I ‘,3 ‘-dibromo-2,6-dimethyl-6,7- 
To a stirred solution of (+)-normetazocine base (2) (0.5 g, 
2.3 mmol) and triethylamine (0.70 g, 6.9 mmol) in acetic acid 
(5.0 ml) at room temperature was added dropwise, for 10 min, 
a solution of bromine (freshly redistilled) (0.74 g, 4.6 mmol) in 
acetic acid (5.0 ml). After the addition was complete, the reac- 
tion mixture was stirred for a further 10 min (complete by TLC; 
solvent system A), and then poured into a mixture of 50 g ice 
and excess concentrated aqueous ammonia. The copious white 
precipitate was filtered (slow) and the solid was washed with 
distilled water (100 ml) and air dried overnight o afford 0.87 g 
(quantitative) of crude 3. Two recrystallizations of 3. HCl from 
5.0 ml of ethyl acetate afforded 0.75 g (79%) of 3bHCl: m.p. 
248-249°C; [alz5D = +67.4’ (c = 0.29, MeOH); anal. talc. 
(Cr4HrsClBrzNO): C 40.86, H 4.41, N 3.40%; found: C 40.99, 
H 4.45, N 3.46%. 
2.4. (+)-cis-2 ‘-Hydroxy-I ‘-bromo-2,6-dimethyl-6,7-benzo- 
morphan (4) 
A solution of 3.HCl 0.30 g, 0.729 mmol) in MeOH (30 ml) 
containing 10% Pd/C (0.30 g) was stirred at room temperature 
and 1 atm. pressure under an atmosphere of hydrogen gas (ex- 
cess). Analysis of the reaction mixture after 2 h byTLC (solvent 
system A) indicated the presence of one major (higher Rr) pro- 
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duct which did not co&grate with the desired (+)- 
normetazocine. Continued hydrogenation failed to effect any 
further change. The reaction mixture was filtered through celite 
and the filtrate was evaporated in vacua to afford a crystalline 
residue (quantitative as 4. HBr salt). The residue was dissolved 
in MeOH (5 ml) and treated with an excess of HBr gas in 
MeOH. Distillation of the MeOH and addition of 2-propanol, 
keeping the volume constant at 10 ml, afforded 4.HBr (0.21 g, 
76%): m.p. 245-246OC; [cy]“D = +60.5” (c = 0.33, MeOH); 
anal. talc. (Ci4Hi9Br2NO): C 44.59, H 5.08, N 3.71%; found: 
C 44.66, H 5.11, N 3.68%. 
2.5. (+)-fH]Normetazocine (rH]-2) 
A solution of 3.HCl (20.0 mg, 0.049 mmol) in 2.0 ml of 
methanolic KOH (2.0%, w/v) containing 20 mg of 10% Pd/C 
was stirred for 2 h at room temperature under an atmosphere 
of carrier-free tritium gas (20.0 Ci, 0.338 mmol). The reaction 
mixture was filtered, evaporated under a stream of argon to 
remove labiles and acidified by dissolving in 25 ml of 2.0% 
acetic acid in MeOH (for storage): activity = 1.80 Ci. The solu- 
tion was evaporated under a stream of nitrogen and the residue 
was treated with water (3.0 ml) followed by concentrated 
aqueous ammonia (3.0 ml). The basified solution was extracted 
with 3 x 3 ml of CHzCl2 and the organic extract was 
evaporated under a stream of nitrogen and applied to one 20 cm 
x 20 cm x 0.5 mm silica gel preparative TLC plate (Analtech 
GF). The plate was eluted with solvent system A and the band 
comigrating with unlabeled (+)-normetazocine (2) was re- 
moved, and extracted with 40 ml of solvent system B. The ex- 
tract was filtered through a plug of glass wool and evaporated 
under a stream of nitrogen. Reconstitution of the residue with 
methanol (50 ml) afforded [‘HI-2 (0.68 Ci, 24% radiochemical 
yield) in greater than 99% radiochemical purity: specific activi- 
ty = 26.6 Ci/mmol (by UV analysis of the solution at A = 
282 nm; 62s~ = 2175 l.mol-‘.cm-’ in MeOH). This material 
was found to be unstable on storage at 13.6 mCi/ml in MeOH 
and was therefore diluted to a final dilution of 1 mCi/ml of 
MeOH. 
2.6. (+)$H]Pentazocine @HI-lb) 
50 ml (50 mCi, 0.00188 mmol) of diluted MeGH stock solu- 
tion of [‘HI-2 was evaporated under a stream of nitrogen gas at 
60°C and the residue was transferred to a small test tube with 
3 X 1 ml of CH2Cl2. The CHFl2 was evaporated under a 
stream of nitrogen gas and to the residue was added 
0.00226 mmol of 4-bromo-2-methyl-2-butene i  110 ,uI of N,N- 
dimethylformamide (DMF) and 0.5 mg of anhydrous 
NaHCOr. The reaction mixture was heated at 60°C under a 
nitrogen atmosphere and after 12 h the reaction was diluted 
with 1 pl distilled water. The aqueous mixture was extracted 
with 2 x 1 ml of CHCls and the organic extract was evaporated 
under a stream of nitrogen. The residue was chromatographed 
on one 20 cm x 20 cm x 0.5 mm preparative TLC plate, eluting 
with solvent system A. The band comigrating with unlabeled lb 
was removed and extracted with 20 ml of solvent system B and 
the extract filtered through a plug of glass wool. Evaporation 
of the solvent under a stream of nitrogen and reconstitution of 
the residue with 3.0 ml of ethanol afforded [‘HI-lb, 4.67 mCi 
(9.3% chemical yield), specific activity 26.6 Ci/mmol. The 
material was adjusted to a final dilution of I mCi/ml of 95% 
EtOH for storage. 
2.1. Receptor-binding studies 
Binding studies were carried out using the crude PZ fraction 
of guinea pig brain. Frozen guinea pig brains (Pel-Freeze, 
Rogers, AK) were allowed to thaw slowly on ice after removal 
of the cerebella. Crude P2 membranes were prepared as 
previously described for rat brain [16]. Membranes were in- 
cubated with the designated concentration of (+ )-[‘HIpen- 
tazocine (26.6 Ci/mmol) and 500 mg of membrane protein in a 
total volume of 500 ~1 of 50 mM Tris-HCl, pH 8.0. Incubations 
were carried out for 120 min at 25°C. Non-specific binding was 
determined in the presence of 10 mM unlabeled (+)- 
pentazocine. Assays were terminated by dilution with 5 ml of 
ice-cold 10 mM Tris-HCl, pH 8.0, and vacuum filtration 
through glass fiber filters (Schleicher and Schuell, Keene, NH) 
using a Brandel Cell Harvester (Gaithersburg, MD). Filters 
were then washed twice with 5 ml of ice-cold 10 mM Tris-HCl, 
pH 8.0. Filters were soaked in 0.5% polyethyleneimine for at 
least 30 min at 25°C prior to use. Filters were counted on a 
Packard model 4450 scintillation spectrometer using Ecoscint 
cocktail (National Diagnostics, Manville, NJ) after overnight 
extraction of counts. 
For Scatchard analysis, 12 concentrations of (+)-[‘HIpen- 
tazocine ranging from 0.05 nM to 25 nM were incubated as 
described above. Data were analyzed using the iterative curve 
fitting program BDATA (EMF Software Inc., Baltimore, MD). 
Competition binding studies were carried out as described 
below. 
3. RESULTS 
We have developed an efficient route (fig.1) to 
high specific activity [3H]-lb starting from (+)- 
normetazocine (2) [3] which renders [3H]-lb 
available for the first time. Thus, dibromination of 
2 (base) in glacial acetic acid afforded (+)- 
cis-2’ -hydroxy-1 ’ ,3’ -dibromo-2,6-dimethyl-6,7- 
benzomorphan (3) in 79% yield. Attempts to 
tribrominate 2 with N,N’-dibromoisocyanuric 
acid in concentrated sulfuric acid [17] were unsuc- 
cessful. Hydrogenation of 3. HCl over 10% Pd/C 
in MeOH afforded the monobromide 4 as the only 
product. The more hindered 1 ‘-bromine of 4 ap- 
peared to be resistant to hydrogenolysis under 
these conditions. However, hydrogenation of 3 in 
2% methanolic KOH in the presence of 10% Pd/C 
proceeded smoothly to give 2, identical by ‘H- 
NMR, TLC and GC to an authentic sample [3]. It 
was therefore necessary to convert 3 to its phenox- 
ide anion before complete hydrogenolysis to 2 was 
possible. Thus, tritiolysis of 3 in 2% methanolic 
KOH in the presence of 10% Pd/C afforded [3H]-2 
in 24% radiochemical yield. This procedure af- 
forded [3H]-2 which was converted to the desired 
[3H]-lb of specific activity 26.6 Ci/mmol in 9.3% 
chemical yield by N-alkylation with 4-bromo-2- 
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(-)-Pentazocina (la) (+)-Pantazocine (1 b) 
3 
T2, 10% Pd/C 
2% KOH, MeOH 
[3H]-2 [3H]-1 b 
x 
I 
Fig.1. Structures of compounds and reaction sequence. 
methyl-2-butene in DMF containing NaHCOs as 
described previously [2]. Racemic [3H]pentazocine 
of low specific activity (0.053 Ci/mmol) has been 
previously synthesized [18] by a route employing 
NaBT4 reduction which is not applicable to syn- 
thesis of high specific activity ligand required for 
receptor-binding studies. Scatchard analysis of 
[3H]-lb binding to guinea pig brain membranes 
was carried out as described in section 2. [‘HI-lb 
exhibited saturable binding with & = 5.13 f 
0.97 nM and Bmax = 1146 + 122 fmol/mg of pro- 
tein. Results are based on the average + SE of two 
experiments, each performed in duplicate. All 
plots are linear suggesting labeling of a single class 
56 
of sites. Specific binding was greater than 90% at 
all concentrations examined (up to 25 nM). 
In order to determine whether [3H]-lb labels 0 
receptors, the ability of several unlabeled com- 
pounds to compete for sites labeled by 13H]-lb was 
determined. Results are shown in table 1. The 
typical 4 receptor ligands haloperidol, DTG, and 
(+)-3-PPP competed with high affinity. (+)- 
Pentazocine bound with higher affinity than ( -)- 
pentazocine, demonstrating proper enantioselec- 
tivity for d sites. PCP bound with low affinity 
while the selective PCP receptor ligand, MK-801, 
was inactive. Finally, the dopamine receptor 
agonist apomorphine, was inactive. This ligand 
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Table 1 
Ligand selectivity of site labeled by (+)-[‘Hlpentazocine 
Ligand IGO (W 
(+)-Pentazocine 5.0 + 0.7 
Haloperidol 5.3 f 0.9 
DTG 45 + 10 
( + )-3-PPP 48 + 2 
(+)-SKF-10,047 97 & 6 
( - )-Pentazocine 136 * 14 
PCP 2871 _t 735 
Apomorphine > 10000 
( + )-MK801 > 10000 
Assays were carried out under the conditions described in 
section 2, using 3 nM [3H)-( +)-pentazocine and 12 
concentrations of unlabeled test ligand ranging from 
0.05-10000 nM. Competition data were analysed using the 
iterature curve fitting program CDATA (EMF Software Inc., 
Baltimore, MD). ICso values are averages of two experiments + 
SE. Each experiment was carried out in duplicate. Greater than 
10000 nM denotes less than 20% inhibition at 10000 nM 
concentration of test drug 
selectivity pattern is identical to that reported for 
sites labeled by ( +)-3-[3H]PPP and [3H]DTG, two 
commonly used d receptor probes [ 12,131. 
4. DISCUSSION 
The results of this study conclude that ( +)- 
pentazocine is amenable to high specific activity 
tritiation and that t3H]-lb labels d sites. The pro- 
totypical c ligands DTG and (+)-3-PPP exhibit 
high affinity for the site labeled by [3H]-lb. The in- 
activity of apomorphine and high potency of 
haloperidol demonstrates failure to label dopa- 
mine receptors, whereas the weak affinity of PCP 
and the absence of potency of MK-801 demon- 
strates failure to label PCP receptors. Thus, 
t3H]-lb binds with high selectivity to a site with 
identical ligand selectivity as the g receptor. 
The high binding affinity of [3H]-lb (I& = 
5.1 nM) is also noteworthy. The only other 
benzomorphan-based radiolabeled c ligand, ( +)- 
[3H]SKF-10,047, has been reported to exhibit a & 
of 40 nM in guinea pig brain membranes [4]. Thus, 
[3H]-lb binds to c sites with about &fold higher af- 
finity than ( +)-[3H]SKF-10,047. This is qualita- 
tively consistent with the results of competition 
against [3H]-lb, where unlabeled ( + )-pentazocine 
exhibited 20-fold higher affinity than unlabeled 
(+ )-SKF-10,047. Compared to (+ )-SKF-10,047, 
the higher affinity of ( + )-pentazocine for g recep- 
tors and its much lower affinity for PCP receptors 
([5,19] and unpublished observations) suggest hat 
[3H]-lb will be a more useful 0 ligand than (+ )- 
[3H]SKF-10,047. The other typical radiolabeled 0 
ligands, ( +)-3-[3H]PPP and [3H]DTG exhibit high 
selectivity for c receptors [12,13]. However, these 
ligands bind with 5-6-fold lower affinity than 
[3H]-lb. The only other radioligand with com- 
parable affinity to t3H]-lb is [3H]haloperidol (Kd 
= 2.0 nM) [12]. However, use of this compound is 
severely limited by its nearly equal affinity for 
dopamine receptors and the necessity to mask 
these receptors in a binding protocols [ 121. 
In summary, the high affinity, high selectivity 
and low level of non-specific binding render 
[3H]-lb a highly suitable tool for study of the 
structure and function of B receptors. This ligand 
offers several advantages over the currently 
available 0 receptor probes. In addition, since re- 
cent evidence suggests that (+)-benzomorphan 
and nonbenzomorphan ligands interact differently 
with Q receptors [20], a better radiolabeled ben- 
zomorphan based ligand probe is needed in order 
to further investigate this phenomenon. A more 
detailed assessment of the binding characteristics 
of (+ )-[3H]pentazocine and a comparison to those 
of other radiolabeled B ligands is therefore war- 
ranted. 
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